Analyst Emily Bodnar of H.C. Wainwright maintained a Buy rating on Genelux Corp., retaining the price target of $31.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Emily Bodnar has given his Buy rating due to a combination of factors tied to both clinical and operational progress at Genelux. The company’s lead asset Olvi-Vec continues to advance in its pivotal Phase 3 OnPrime trial for platinum-resistant ovarian cancer, with the independent data monitoring committee recently endorsing continuation without changes, supporting the therapy’s safety profile and the likelihood of reaching a meaningful data readout in 2H26.
Beyond ovarian cancer, early results in small cell and non-small cell lung cancer show promising response and disease control rates in heavily pretreated patients, hinting at a potential efficacy advantage over historical benchmarks. At the same time, Genelux is proactively upgrading its in-house manufacturing facility with automation and process improvements that align Phase 3 and future commercial production, which Bodnar views as lowering regulatory and commercial execution risk and supporting long-term value creation for shareholders.
According to TipRanks, Bodnar is a 4-star analyst with an average return of 5.6% and a 33.68% success rate. Bodnar covers the Healthcare sector, focusing on stocks such as NovoCure, Acrivon Therapeutics, Inc., and Agenus.
In another report released on March 6, Maxim Group also maintained a Buy rating on the stock with a $12.00 price target.